| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1015511J |
| P356 | DOI | 10.1371/JOURNAL.PONE.0115511 |
| P932 | PMC publication ID | 4304839 |
| P698 | PubMed publication ID | 25616135 |
| P5875 | ResearchGate publication ID | 273284358 |
| P50 | author | Timothy B Hallett | Q85639231 |
| Jared M Baeten | Q89443633 | ||
| Sinead Delany-Moretlwe | Q42572161 | ||
| Ide Cremin | Q55523400 | ||
| Michael R. Pickles | Q56134572 | ||
| Connie Celum | Q42571941 | ||
| P2093 | author name string | Britta L Jewell | |
| P2860 | cites work | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 |
| Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women | Q24629582 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| HIV-1 prevention for HIV-1 serodiscordant couples | Q26996011 | ||
| Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q27860791 | ||
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial | Q28292876 | ||
| The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies | Q28487926 | ||
| Recurrence rates in genital herpes after symptomatic first-episode infection | Q72852714 | ||
| Synergistic copathogens--HIV-1 and HSV-2 | Q79808081 | ||
| Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial | Q43932977 | ||
| Herpes simplex virus type 2: a key role in HIV incidence | Q45383723 | ||
| Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time | Q45748671 | ||
| Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women | Q45790547 | ||
| Prior herpes simplex virus type 2 infection as a risk factor for HIV infection | Q45842052 | ||
| Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study | Q46863163 | ||
| Male circumcision for HIV prevention: from evidence to action? | Q47706900 | ||
| Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa | Q28533158 | ||
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana | Q29620078 | ||
| Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial | Q33313869 | ||
| Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study | Q33436735 | ||
| New concepts in understanding genital herpes | Q33582145 | ||
| Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. | Q33727305 | ||
| HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention | Q33763000 | ||
| Effect of early versus deferred antiretroviral therapy for HIV on survival | Q33789114 | ||
| Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis | Q34067511 | ||
| Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study | Q34081339 | ||
| Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review | Q34152197 | ||
| Once-daily valacyclovir to reduce the risk of transmission of genital herpes | Q34287411 | ||
| Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes | Q34556854 | ||
| Persistent genital herpes simplex virus-2 shedding years following the first clinical episode | Q34682912 | ||
| Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor | Q34780464 | ||
| Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy | Q35214949 | ||
| Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. | Q35562429 | ||
| The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics | Q35691394 | ||
| Efficacy results of a trial of a herpes simplex vaccine | Q35780697 | ||
| Effectiveness of condoms in preventing sexually transmitted infections | Q35882388 | ||
| Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies | Q36188123 | ||
| Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. | Q36331074 | ||
| The determinants of HIV treatment costs in resource limited settings | Q36381028 | ||
| Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey | Q36595760 | ||
| Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies | Q36941573 | ||
| Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Q37042094 | ||
| Incident HSV-2 infections are common among HIV-1-discordant couples | Q37145745 | ||
| Male circumcision for the prevention of HSV-2 and HPV infections and syphilis | Q37178782 | ||
| Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial | Q37212998 | ||
| The burden of disease and injury in Iran 2003. | Q37262767 | ||
| Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices | Q37505057 | ||
| Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial | Q38861991 | ||
| Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda | Q38885289 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | South Africa | Q258 |
| Human herpesvirus 2 | Q18965147 | ||
| P304 | page(s) | e0115511 | |
| P577 | publication date | 2015-01-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa | |
| P478 | volume | 10 |
| Q57178454 | Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand |
| Q89905960 | Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel |
| Q36654828 | Modeling and Cost-Effectiveness in HIV Prevention |
| Q37352564 | Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa |
| Q54233736 | Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. |
| Q56910975 | The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa |
| Q38742497 | The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection |
Search more.